Compare IDEXX Laboratories, Inc. (IDXX) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Tempus AI — how do they compare? IDEXX Laboratories, Inc. trades at $572.77 (market cap $46.22B), while Tempus AI trades at $54.4 (market cap $10.05B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.6× Tempus AI's market cap. Which is the better fit depends on your goals.
| IDXX | TEM | |
|---|---|---|
Market Cap | $46.22B | $10.05B |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $103.25 |
52-Week Low | $526.44 | $41.55 |
Enterprise Value | $47.12B | $10.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Tempus AI (TEM) trades at $54.99, down 0.13% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed a narrower loss than expected and revenue beat, driving positive sentiment. The company is expanding through acquisitions like Personalis and launching new services, though it remains unprofitable with negative margins.
The outlook is cautiously optimistic due to revenue growth and strategic initiatives, but high valuation ratios and persistent losses pose risks. Upside is supported by a $61.57 consensus price target, while competitive and execution challenges require monitoring for sustained investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
